NPS Pharmaceuticals (NPSP) Inactive 10-K2002 FY Annual report

Filed: 21 Mar 03, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: abandon, accuracy, aid, Albany, Alpharma, altogether, amenable, amplification, Analyst, antidepressant, Antitrust, architecturally, aRNA, arrest, assignee, attendance, attended, Austria, automatic, automatically, award, awarded, bad, Bank, banking, Bay, bear, BI, bioscience, biotech, Boehringer, breadth, Bringing, brown, Cambrex, carcinogenicity, cardiology, cardiovascular, career, cautionary, CEO, certify, certifying, CFA, cinacalcet, circumstance, clearance, CNS, complicated, confusingly, contrary, Coping, correct, corrected, corrective, correlated, court, CPL, CV, Cygne, defending, dehydration, denominated, deterioration, Developmental, Diagnostic, directorship, dissolution, diverted, doubtful, draft, drop, eighteen, Einstein, electronically, Endocrine, Engineering, entirety, Enzon, exact, expedite, expressly, faculty, fast, fellow, female, femoral, filer, fill, fluid, forfeiture, formula, fraud, freedom, fullest, furnish, furnished, George, Gerard, Glaxo, global, GmbH, guarantee, guarantor, Guilford, Hamilton, harbor, HCl, headache, heavily, Hemosol, Histological, hyperparathyriodism, implied, Indirect, individual, inflammation, Ingelheim, injector, inserted, Internet, interpretation, Joseph, Justice, Kaufmann, Klein, Layton, LBS, LC, learning, Lederle, light, LLC, Lorna, malabsorption, malnutrition, Manchester, mandatory, manifested, ManuPharm, Maupin, MDS, Medeva, medium, member, membership, memory, methodology, Michel, Microbiology, misleading, monitizing, monthly, moral, morgan, morphology, moving, multidisciplinary, multitude, narrow, Neurobiology, Neuroscience, neurotransmitter, Newton, NMDA, nominee, noncontingent, Ohio, omit, optionee, overcome, owner, PaineWebber, Parrish, Parsipanny, passed, PEG, Pennsylvania, perception, permitted, permitting, Pharma, Pharmacy, physician, plagued, powder, precipitation, premium, presumption, procurement, rata, ready, reclassified, reconstituted, refined, refrigeration, regularly, relationship, relocation, remeasured, reoccur, Reorganization, replicate, resection, residence, Ribapharm, Richmond, Rochester, Roerig, Rorer, Rowe, Rygiel, salary, Saskatchewan, SCA, sedation, sound, spasticity, specialty, Spectral, spent, spouse, St, stability, stable, stand, Stanford, startup, Stephen, strictly, subordinated, survey, Task, Taylor, telephone, terminology, terraparitide, threat, Torstar, track, Transnational, twenty, unanimously, understanding, unexercised, unfeasible, unfunded, uniform, unlawful, unmet, untrue, urgent, vacuolization, variability, variable, vendor, VIE, VivoQuest, wall, website, Wharton, whereunder, Winder, winding, withhold, York

Removed: allocation, ALX, assigned, assumed, Attorney, binding, canceled, caption, cautioned, constituted, converted, deny, dose, estimating, expand, Expiring, facility, fed, formal, GATX, inefficient, intensely, Intent, intravenously, investing, jurisdiction, Kellogg, KPMG, level, LLP, marked, merrell, neurological, nonrecurring, Northwestern, obligate, occurred, permanently, phosphate, preclude, presently, pursuit, recovery, robert, SIDDCO, speak, Supplemental, technique, Treasurer, undue

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

NPSP similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 10.8G

January 24, 2000

NPS Pharmaceuticals, Inc.
420 Chipeta Way
Salt Lake City, Utah 84108

RE: Amendment Agreement to Amend the November 26, 1997 Amendment Agreement

Dear Sirs:

This Amendment Agreement to Amend the November 26, 1997 Amendment Agreement (hereinafter “January 24, 2000 Amendment Agreement”) will confirm that the Letter Agreement dated November 26, 1997 between NPS Pharmaceuticals, Inc., a corporation of the state of Delaware, having a place of business at 420 Chipeta Way, Salt Lake City, Utah 84108, U.S.A. (herein referred to as “NPS”) and SmithKline Beecham Corporation, a corporation of the Commonwealth of Pennsylvania, having a place of business at One Franklin Plaza, Philadelphia, Pennsylvania 19101, U.S.A. (hereinafter referred to as “SB”) shall be amended, effective as of the date of NPS' signature below, as follows:

	•	In the second bullet, delete the “fifth, sixth, and seventh RESEARCH years” and insert therefor the words “fifth and sixth RESEARCH years”, and at a level of one hundred seventy five thousand U.S. dollars (U.S. $175,000) per NPS FTE who is a lab personnel and at a level of one hundred fifty thousand U.S. dollars (U.S. $150,000) per NPS FTE who is a non–lab based consultant for the seventh RESEARCH year, provided that it is understood that there will only be a total of two (2) NPS FTE's during the seventh RESEARCH year, and the levels outlined above will be applied on a pro-rata basis depending on the type of NPS FTE utilized.
	•	This January 24, 2000 Amendment Agreement shall be retroactively effective as of November 1, 1999.

	•	All other terms and conditions of the Letter Agreement shall remain in full force and effect.

One Franklin Plaza, PO Box 7929, Philadelphia, PA 19101.Telephone (215) 751 4000. ^–Fax (215) 751 3400.

Please indicate your acceptance of this January 24, 2000 Amendment Agreement by signing and dating the duplicate copies of this letter below and returning one such fully executed copy to SB.

Very truly yours,

SMITHKLINE BEECHAM CORPORATION

By: /s/ Donald F. Parman

					Donald F. Parman
					Title: Secretary

Date: January 24, 2000

AGREED TO AND ACCEPTED: NPS PHARMACEUTICALS, INC.

By:	/s/ E. F. Nemith
	E. F. Nemith
Title:	CSO
Date:	1/31/2000